Quick read
Fair Value Engine
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot
DBX stock price vs RH: inconclusive
Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Price gap
N/A
Coverage
Medium · 60%
Free account · revisit it from your workspace
Quick read
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Latest stored price
Metric-by-metric
Filter, sort, and scan where each company leads, where gaps are small, and where comparisons are not meaningful.
| Metric | DBX | RH | Spread |
|---|---|---|---|
Revenue growth (YoY) DBX: FY 2024 -> FY 2025 | RH: FY 2025 -> FY 2026 | -1.1% | 8.1% | RH leads by 113.1% Higher Revenue growth |
Gross margin | 80.1% | 44.1% | DBX leads by 81.8% Higher Gross margin |
EBITDA margin | 36.8% | 22.0% | DBX leads by 67.7% Higher EBITDA margin |
EV/Revenue | N/M | N/M | Insufficient data No additional context |
P/E | N/M | N/M | Not comparable Not comparable |
Net debt / EBITDA | 3.1 | -0.2 | RH leads by 1387.5% Lower Net debt / EBITDA |
Statements
Core income statement and balance sheet metrics aligned to the reporting windows.
| Metric | DBX | Delta vs RH | RH |
|---|---|---|---|
| Revenue | $2.52B | 26.7% lower | $3.44B |
| Gross profit | $2.02B | 33.3% higher | $1.52B |
| Operating income | $689.10M | 77.9% higher | $387.27M |
| EBITDA | $928.60M | 22.9% higher | $755.50M |
| Net income | $508.40M | 307.4% higher | $124.79M |
| EPS | 1.9 | 70.5% lower | 6.3 |
| Revenue growth | -1.1% | 113.1% lower | 8.1% |
| Gross margin | 80.1% | 81.8% higher | 44.1% |
| Operating margin | 27.3% | 142.8% higher | 11.3% |
| EBITDA margin | 36.8% | 67.7% higher | 22.0% |
| Net margin | 20.2% | 455.9% higher | 3.6% |
Trendline
Track multi-year revenue, earnings, and margin direction before underwriting a rerating.
Price framework
Market cap + debt - cash, shown for the current pair and benchmark median context.
Price framework
Baseline discounted cash flow model estimating total intrinsic firm value first, then bridging to an implied stock price per share.
Risk control
Financial health checks to separate durable balance sheets from potential value traps.
Comparable set
Place both companies in context relative to a wider comparable universe.
LLM-powered Synthesis
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
DBX screens as much higher quality and cheaper than RH on earnings and cash-generation proxies, but the valuation gap is partially tempered by DBX's negative growth and weak balance-sheet quality signals.
If you believe DBX can stabilize growth while maintaining its superior margins, then buying DBX is reasonable because its P/E is below RH's and its profitability is materially stronger despite softer revenue growth.
DBX trades at 15.4x P/E versus RH at 26.8x, which supports a relative value case for DBX on earnings-based multiples. However, RH is far cheaper on sales and EBITDA multiples, so the valuation picture is mixed rather than an outright discount story.
Supporting Metrics